Research Provides Important Insight Into ‘Systemizing’ Theory Of Autism
Wednesday, Aug. 3rd 2011 6:40 AM
A new study from Cambridge University has for the first time found that autism diagnoses are more common in an IT-rich region. The Medical Research Council (MRC) funded study, published in the Journal of Autism and Developmental Disorders, has important implications for service provision in different regions and for the ‘hyper-systemizing’ theory of autism.
Related posts:
- Autism Families With New Pregnancies Sought For Vitamin D Research Associate Professor Emeritus of Psychiatry and Pediatrics (OHSU, Portland, Oregon) is seeking roughly 50-100 volunteer families to participate in a vitamin D study. The goal of the study is to find out whether giving Vitamin D to the pregnant mother, who already has had at least one previous child with autism, can prevent the recurrence […]...
- Genetic Causation Of ASD Appears To Be Highly Diverse; Thoughts On Why Fewer Girls Have Autism A clinically extensive and mathematically powerful study of 1000 families with one autistic child and one unaffected sibling has validated a controversial theory of autism’s complex genetic causation. The study for the first time estimates the minimum number of locations in the human genome — 250 to 300 — where gene copy number variation (CNV) […]...
- Weaker Brain "Sync" May Be Early Sign Of Autism In a novel imaging study of sleeping toddlers, scientists at the University of California, San Diego Autism Center of Excellence report that a diminished ability of a young brain’s hemispheres to “sync” with one another could be a powerful, new biological marker of autism, one that might enable an autism diagnosis at a very young […]...
- Autism-Related Study Discovers How Drug Interferes With Neuronal Cell Function A York University study has shown for the first time how the drug misoprostol, which has been linked to neurodevelopmental defects associated with autism, interferes with neuronal cell function. It is an important finding because misoprostol is similar in structure to naturally-occurring prostaglandins, which are the key signaling molecules produced by fatty acids in the […]...
- Study Aims To Uncover Source Of Sensory Problems In Autism The way the brain reacts differently to the sense of touch in people with Autism will be examined as part of an innovative Cardiff University study designed to create better understanding of the condition in Autism....
- Johns Hopkins Researchers Create New Mouse Model Of Autism In an effort to unravel the tangled biology of autism, Johns Hopkins scientists have created a mouse model that mimics a human mutation of a gene known to be associated with autism spectrum disorders. Experiments with the engineered mouse reveal a molecular mechanism by which mutations of the gene named Shank3 affect the brain and […]...
- Researchers Develop Mouse Model To Help Find How A Gene Mutation Leads To Autism Researchers Develop Mouse Model To Help Find How A Gene Mutation Leads To Autism...
- Disruption Of Neural Activity In Autistic Toddlers A new study provides valuable insight into the neuropathology of early autism development by imaging the brains of naturally sleeping toddlers. The research, published by Cell Press in the June 24 issue of the journal Neuron, identifies a brain abnormality observed at the very beginning stages of autism that may aid in early diagnosis of […]...
- McMaster Researchers Say Routine Screening For Autism Not Needed Proposals recommending routine screening of all children for autism gets a thumbs down from researchers at McMaster University. In a study in the online edition of the journal Pediatrics, the researchers say there is “not enough sound evidence to support the implementation of a routine population-based screening program for autism....
- Seaside Therapeutics Initiates Phase 2b Study Of STX209 In Autism Spectrum Disorders Seaside Therapeutics, Inc. announced today the initiation of a randomized, double-blind, placebo-controlled Phase 2b study to evaluate the effects of STX209 (arbaclofen) on social impairment in children, adolescents and adults (ages 5 to 21) with autism spectrum disorders (ASD). The Company announced positive results from an open-label Phase 2a study of STX209 in September of […]...
- New Technology Reveals A Unique Vocal Signature In Autism A new automated vocal analysis technology could fundamentally change the study of language development as well as the screening for autism spectrum disorders and language delay, reports a study in the July 19 online Proceedings of the National Academy of Sciences…...
- Study Linking Autism To MMR Vaccine “An Elaborate Fraud” Study Linking Autism To MMR Vaccine "An Elaborate Fraud"...
- Grants Announced for University Centers for Excellence in Developmental Disabilities Education, Research & Service (UCEDD) – Application Deadline February 15 Grants Announced for University Centers for Excellence in Developmental Disabilities Education, Research & Service (UCEDD) - Application Deadline February 15...
- Why is it important to buy a Medigap policy when I am first eligible? The best time to buy a Medigap policy is during your Medigap open enrollment period. This period lasts for 6 months and begins on the first day of the month in which you’re both 65 or older and enrolled in Medicare Part B. Some states have additional open enrollment periods including those for people under 65. During this period, an insurance company can’t use medical underwriting. This means the insurance company can’t do any of the following because of your health problems: • Refuse to sell you any Medigap policy it sells • Make you wait for coverage to start (except as explained below) • Charge you more for a Medigap policy While the insurance company can’t make you wait for your coverage to start, it may be able to make you wait for coverage if you have a pre-existing condition. A preexisting condition is a health problem you have before the date a new insurance policy starts. In some cases, the Medigap insurance company can refuse to cover your out-of-pocket costs for these pre-existing health problems for up to 6 months. This is called a “pre-existing condition waiting period.” After 6 months, the Medigap policy will cover the pre-existing...
Posted on Wednesday, Aug. 3rd 2011 6:40 AM | by Share of Cost | in Share of Cost | No Comments »